88.64
-1.87%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Imeik Technology Development Co
Its shares trade on Shenzhen under the ticker 300896.SZ. It has been listed since 28 September 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.42bn and net income of CN¥1.29bn. At that date it held total assets of CN¥8.91bn and shareholders' equity of CN¥7.58bn.
Imeik Technology Development Co., Ltd. engages in the research, development, and transformation of biomedical materials, with a focus on recombinant proteins and peptides. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-09-28. The firm focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The firm has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The firm's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The firm mainly conducts its businesses in the China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Sept 2020
- Employees
- 713
- Website
- imeik.net ↗
Leadership
Pay as last reported
- Ms. Jun JianChairman of the Board, since 2016CN¥2.5m
- Mr. Renchao ZhangFinance Director (Chief Financial Officer), Director, since 2021CN¥2.3m
- Mr. Yifeng ShiGeneral Manager, Director, since 2016CN¥2.7m
- Ms. Lina GouDeputy General Manager, Chief Sales OfficerCN¥2.7m
- Ms. Yonglei YinDeputy General ManagerCN¥2.7m
- Mr. Yong JianSecretary of the Board, Director, since 2016CN¥2.1m
- Mr. Xinyang LinDirectorCN¥186,800
- Mr. Lanzhu WangDirectorCN¥186,800
- Mr. Gang ChenIndependent DirectorCN¥186,800
- Mr. Yuqun YuIndependent DirectorCN¥186,800
- Mr. Daqi ZhuIndependent DirectorCN¥186,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 88
- Social
- 99
- Governance
- 77
- Direct emissions (scope 1)
- 1,251.54 t
- Energy emissions (scope 2)
- 3,609.92 t
- Women in the workforce
- 46.44317%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Imeik Technology Development Co Ltd focuses on recombinant proteins and peptides for biomedical materials.
- The company has industrialized injection-type sodium hyaluronate series products in China.
- Imeik's self-developed products target facial and neck skin repair in medical cosmetology.
Weaknesses
- Imeik Technology Development Co Ltd operates solely in the China market without international expansion.
- The company has no mention of partnerships with global healthcare providers or distributors.
- Imeik's business is limited to biomedical materials without diversification into other health sectors.
Opportunities
- Imeik can expand into medical cosmetology applications for facial and neck skin repair in China.
- The firm may leverage its product technology transformation platform for medical chitosan in China.
- Imeik could grow by targeting surgical repair and metabolic disease treatments in China.
Threats
- Imeik Technology Development Co Ltd faces competition from domestic biotechnology firms in China.
- The company's reliance on the China market exposes it to regional economic fluctuations.
- Imeik's focus on biomedical materials may limit its ability to respond to emerging health trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.